FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HAMMONS KEVIN J					COI	2. Issuer Name and Ticker or Trading Symbol COMMUNITY HEALTH SYSTEMS INC [CYH]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner					
(Last) 4000 ME	ast) (First) (Middle)				3. Dat	3. Date of Earliest Transaction (Month/Day/Year) 03/01/2017									X Officer (give title Other (s below)  Senior VP and CAO				
(Street) FRANKLIN TN 37067				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting					
(City) (State) (Zip)						Person													
		Tabl	eI-N					Ac		Dis				Ily Owned					
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/			//Year)	Executio		•	3. Transaction Code (Instr. 8)		4. Securities Acquired (, Disposed Of (D) (Instr. 3 and 5)			Securiti Benefic Owned Followi	es ially	Form (D) o	n: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) o (D)	Price	Reporte	ed ction(s)		,	(111341. 4)		
Common Stock 03/01/2					017		A		12,5000	1) <b>A</b>	\$0.0	00 85	85,873		D				
Common Stock 03/01/20							F		12,586	5 D \$9.19			73,287		D				
			Tab	le II - Deri (e.g.							osed of, o onvertible			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	eemed tion Date, h/Day/Year)	4. Transacti Code (Ins 8)				6. Date Exercisable Expiration Date (Month/Day/Year)		te	nd 7. Title and Amount of Securities Underlying Derivative Security (Ir and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e Ownes For ally Director I g (I) (I	Ownership Form: Direct (D) or Indirect (I) (Instr.	Beneficial Ownership	
					Code	v	(A) (D)		Date Exercisal	ole	Expiration Date	Title	Amour or Number of Shares	r					
Performance Based Restricted	\$0.00	03/01/2017			A		12,500		03/01/202	.0 <sup>(2)</sup>	02/28/2027	Common Stock	12,500	\$0.00	12,50	0	D		
Stock Options (Right to Buy)	\$28.7								02/27/20	109	02/26/2018	Common Stock	1,500		1,500	)	D		
Stock Options (Right to Buy)	\$30.32								02/24/20	11	02/23/2020	Common Stock	1,000		1,000	)	D		
Stock Options (Right to Buy)	\$34.38								02/23/20	12	02/22/2021	Common Stock	1,000		1,000	)	D		
Stock Options (Right to Buy)	\$17.49								02/16/20	013	02/15/2022	Common Stock	4,000		4,000	)	D		

## **Explanation of Responses:**

## Remarks:

<sup>1.</sup> The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant.

<sup>2.</sup> The vesting of 80% of these performance-based restricted shares is subject to the attainment of a pre-determined level of Cumulative Same-Store Adjusted EBITDA Growth between January 1, 2017 and December 31, 2019 (the "Performance Period"). The vesting of the remaining 20% of these performance-based restricted shares is subject to the attainment of a pre-determined level of Cumulative Adjusted EPS for the Performance Period. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the target number of performance-based restricted shares subject to the attainment of the Cumulative Same-Store Adjusted EBITDA Growth and Cumulative Adjusted EPS criteria, as applicable, will ultimately vest on the third anniversary of the date of grant, with the vesting percentage to be determined based upon achievement with respect to the applicable criteria during the Performance Period.

NOTE: The per share exercise price of each option listed on Table II granted prior to April 29, 2016, was adjusted pursuant to the Employee Matters Agreement between the Issuer and Quorum Health Corporation ("QHC"), dated as of April 29, 2016, to preserve the aggregate intrinsic value of the original award as a result of the spin-off from the Issuer of QHC, effective April 29, 2016.

Christopher G. Cobb, Attorney in Fact for Kevin J. Hammons

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.